Please join us in welcoming Previse to our bwtech community!

Previse is a pioneering molecular diagnostics company on a mission to save lives through the prediction and earlier detection of cancer, starting with esophageal cancer. Esophageal cancer is one of the most lethal cancers in the world, with a 20% five-year survival rate after diagnosis.

To address this problem, Previse offers Esopredict™, a revolutionary methylation-based assay that provides prognostic information to help gastroenterologists identify patients with Barrett’s esophagus that are likely to progress to high grade dysplasia or esophageal cancer. Barrett’s esophagus is a cancer precursor condition in which the tissue lining the esophagus changes and becomes more like the tissue that lines the intestines. Barrett’s esophagus typically arises from prolonged acid reflux or gastroesophageal reflux disease (GERD). For patients at risk of developing esophageal cancer, Esopredict empowers gastroenterologists to implement effective treatment strategies sooner – a crucial advancement toward improving survival rates.

Previse’s technology was made possible by grants from the National Institutes of Health and developed after decades of research by Previse Co-Founder and CMO, Dr. Stephen Meltzer, and his GI Early Detection Biomarker Lab at Johns Hopkins University School of Medicine. “After dedicating decades of my career to cancer research, I am proud to launch Esopredict with the Previse team.”

Daniel Lunz, Co-Founder and CEO of Previse, states, “Our pioneering effort to introduce a first-of-its-kind test to market is a testament to our unwavering commitment to offer advanced solutions to gastroenterologists in their pursuit of providing a proactive and personalized approach to the treatment of Barrett’s esophagus and the prevention of esophageal cancer. We look forward to empowering individuals who are predisposed to this disease, along with their physicians, with the ability to make informed and rapid treatment decisions, leading to lives saved.”

Learn more about Previse and Esopredict by visiting: